NCT01891851View on ClinicalTrials.gov

A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Healthy
Interventions
DRUG

TMC435350 200 mg

Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2

DRUG

Ritonavir 100 mg

Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2

Trial Locations (1)

Unknown

Aalst

All Listed Sponsors
lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT01891851 - A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers | Biotech Hunter | Biotech Hunter